NIH unveils clinical trial supply facility; plans service expansion

The NIH Clinical Center's Pharmaceutical Development Section is readying to cash in on a seven-year effort by moving into a new $12-million facility. The June move to the 1,115-square-meter drug-making plant marks a big change from the 743-square-meter workspace it has occupied for 50 years.

The PDS's 20 chemists, pharmacists, pharmacokineticists and technicians produce investigational treatments used in many of the hundreds of the Clinical Center's ongoing studies--about one-third of the 1,000 drugs, including placebos. Drug forms include solid oral dosage, injection, IV, ointments and creams.

NIH hosted reporters on a walk-through in late March.

The center's plans include services provided not just to on-site NIH researchers and clients but also to outside clinical investigators. The current one-shift operation is eventually expected to run 24/7.

- read the article

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.